CClinicalTrials.gg
CompletedNCT03864822Updated Dec 11, 2020

Enhancing Inhibition With tDCS in Low Back Pain

An interventional study of High-Definition Transcranial Direct Current Stimulation in Low Back Pain, sponsored by Aalborg University. Completed at 1 site in Denmark. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2020-12-11.

Sponsored by Aalborg University · Not applicable, Interventional, and Basic science

Phase
Not applicable
Study type
Interventional
Enrollment
12
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Study summary

This cross-over study intends to use consecutive days of active versus sham transcranial direct current stimulation (tDCS) to enhance descending inhibition and look at resulting clinical effects in people with low back pain.

02

Conditions studied

  • Low Back Pain
03

In context

Back Pain

2,373 studies on the registry are indexed under Back Pain; 284 are open to participants now.

This study's enrollment of 12 is below the median of 60 across 1,941 interventional studies indexed under Back Pain.

Browse Back Pain studies →

Lead sponsor

Aalborg University is the lead sponsor of 178 studies on the registry; 37 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Otherwise healthy men and women
  • Aged 18-60 years
  • Continuous pain (>3days pain/week) episode lasting at least 3 months, sufficient to limit daily activities
  • Pain in the region posteriorly between the inferior border of the 12th rib and the lower gluteal fold (low back pain) at the time of recruitment
  • Able to speak, read and understand English

Exclusion criteria

Exclusion Criteria:

  • Pregnancy
  • Low back pain associated with menstruation
  • Currently seeking active treatment for low back pain
  • Red flags symptoms (i.e. fever, malaise, progressive neurologic deficit, significant trauma, prolonged corticosteroid use or osteoporosis, pain worst at night, urinary or faecal incontinence, or unintended weight loss)
  • Drug addiction defined as the use of cannabis, opioids or other drugs
  • Current or previous neurologic, musculoskeletal, mental, or other illnesses which may affect the trial
  • Current or previous chronic or recurrent pain condition other than low back pain
  • Current regular use of analgesic medication or other medication which may affect the trial
  • Lack of ability to cooperate
05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
12 participants (actual)

Study arms

  • Experimental
    Active tDCS

    30s ramp to 2mA with 20 minute session of active High-Definition Transcranial Direct Current Stimulation at 2mA

    Device: High-Definition Transcranial Direct Current Stimulation

  • Placebo comparator
    Sham tDCS

    30s ramp to 2mA with High-Definition Transcranial Direct Current Stimulation, then device stops stimulating for 20 minutes

    Device: High-Definition Transcranial Direct Current Stimulation

Interventions

  • DeviceHigh-Definition Transcranial Direct Current Stimulation

    Device uses an array of electrodes over the scalp, in contact via gel, to provide a weak electrical current.

06

What researchers measure

Primary outcomes

  1. Conditioned Pain Modulation

    Change in cuff pain threshold with contralateral cuff conditioning stimulus

    Time frame: Day 0 (Pre) to Day 3 (Post) in each stimulation phase

Secondary outcomes

  1. Temporal Summation of Pain

    Change in pain intensity ratings (i.e. on an electronic Visual Analogue Scale from 0=no pain to 10=worst pain imaginable) across series of 10 x 1s cuff stimuli at 0.5Hz (scores are normalized to first rating by subtraction and grouped into 3 epochs of 3 inflations with higher change scores indicating higher summation/facilitation)

    Time frame: Day 1 (Pre) to Day 3 (Post) in each stimulation phase

  2. Pressure Pain Thresholds

    Handheld algometry over the extensor carpi radialis, upper trapezius, lower back and gastrocnemius muscles

    Time frame: Day 1 (Pre) to Day 3 (Post) in each stimulation phase

  3. Pain Intensity

    Visual Analogue Scale from 0=no pain to 10=worst pain imaginable currently at rest and with worst movement, as well as maximum in past week

    Time frame: Day 0 (Pre) to Day 3 (Post) and 2 weeks post for each stimulation phase

  4. Pain Unpleasantness

    Visual Analogue Scale from 0=not unpleasant at all to 10=most unpleasant sensation imaginable currently at rest and with worst movement, as well as maximum in past week

    Time frame: Day 0 (Pre) to Day 3 (Post) and 2 weeks post for each stimulation phase

  5. Pain Area

    Total number of pixels coloured on an electronic body chart (Navigate Pain)

    Time frame: Day 0 (Pre) to Day 3 (Post) and 2 weeks post for each stimulation phase

  6. Roland-Morris Disability Questionnaire

    Measures back-related disability for 24 statements of potentially afflicted tasks with dichotomous responses. Minimum 0 to maximum 24 with higher scores indicating worse disability.

    Time frame: Day 0 (Pre) to Day 3 (Post) and 2 weeks post for each stimulation phase

  7. Back Performance Scale

    5 Task scale rated as per performance as a functional measure of back-related disability (each task is rated on a 4 point Likert scale 0-3 and summed to give total), scored from 0-15 with higher scores indicating more pain and dysfunction during task performance. Here will be used to characterize functional disability.

    Time frame: Day 0 (Pre) to Day 3 (Post) and 2 weeks post for each stimulation phase

Other outcomes

  1. Flanker Task Learning

    Reaction time to selective attention based computer task

    Time frame: Day 0 (Pre) to Day 3 (Post) and 2 weeks post for each stimulation phase

  2. Affect Manipulation

    Effect of image watching on ratings of mood and arousal. Mood and arousal will be measured with the Self Assessment Manikin - a 9 point Likert-type scale with 1 representing most negative/most calm, 5 as neutral, and 9 as most positive/most aroused.

    Time frame: Day 0 (Pre) to Day 3 (Post) and 2 weeks post for each stimulation phase

07

Study locations

1 site
  • CNAP, SMI, Aalborg University
    Aalborg, 9000, Denmark
08

References and documents

Publications

  • McPhee ME, Graven-Nielsen T. Medial Prefrontal High-Definition Transcranial Direct Current Stimulation to Improve Pain Modulation in Chronic Low Back Pain: A Pilot Randomized Double-blinded Placebo-Controlled Crossover Trial. J Pain. 2021 Aug;22(8):952-967. doi: 10.1016/j.jpain.2021.02.012. Epub 2021 Mar 4. PubMed 33676009 ↗

Individual participant data

Plan to share: Undecided — Data will be shared after study completion and publication in necessary cases on request

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Dec 11, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03864822
Lead sponsor
Aalborg University
Collaborators
Danish National Research Foundation
Responsible party
Megan McPhee (Principal Investigator, Aalborg University) — Principal investigator
First posted
Mar 6, 2019
Start date
Apr 29, 2019
Primary completion
Oct 7, 2020
Completion
Oct 7, 2020
Last update
Dec 11, 2020

Study contacts

Megan E McPhee, BPhty MSc
principal investigator · Center for Neuroplasticity and Pain (CNAP), SMI, Aalborg University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion